Immix Biopharma, Inc.IMMXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank17
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-15.45M
↓ 105% vs avg
Percentile
P17
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-7.55M
Historical baseline
PeriodValueYoY Change
TTM$-15.45M+2.0%
2024$-15.77M-38.1%
2023$-11.42M-54.2%
2022$-7.41M-365.9%
2021$-1.59M-292.9%
2020$-404694.00+49.2%
2019$-797340.00-